KNOWLEDGE BANK

Interviews

Mitochondrial “swap” in the Tumor Microenvironment

Professor, Okayama University
Yosuke Togashi MD PhD is a Professor at Okayama University specializing in tumor microenvironment research He trained in respiratory medicine earned his PhD in genome biology and began cancer immunology research in

Articles

Kinase Inhibitors as Antiviral Agents

The emergence of virus infections is a serious issue and the development of broadly acting antivirals has heightened concern for future viral epidemics The majority of these drugs operate directly on the proteins encoded by the individual viral genome However they have the following disadvantages i limited treatment coverage which does not address

Research Insights

An Agent-based Model of Metabolic Signaling Oscillations in Bacillus Subtilis Biofilms

Microbes of nearly every species can form biofilms communities of cells bound together by a selfproduced matrix It is not understood how variation

Case Studies

Rapid, Comprehensive, And Aff Ordable Mycobacterial Diagnosis With Whole-genome Sequencing: A Prospective Case Study

Abstract Background Slow and cumbersome laboratory diagnostics for Mycobacterium tuberculosis complex MTBC risk delayed treatment and poor patient outcomes Wholegenome sequencing WGS could potentially provide a rapid and comprehensive diagnostic solution In this prospective study we compare realtime

Techno Trends

Kansas City University Discovered New Cancer Treatment

Researchers at Kansas City University have made a breakthrough in treating pancreatic cancer by repurposing the FDAapproved drug Acipimox originally designed to treat hyperlipidaemia

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Advanced Drug Delivery Systems for Chronic Liver Disease Management

Jyothi U. Menon

Jyothi U Menon received her PhD in Biomedical Engineering from the University of Texas (UT) Arlington and UT Southwestern Medical Center joint program. She completed her postdoctoral training at the University of Oxford, UK. She is currently an Associate Professor in the College of Pharmacy at the University of Rhode Island where her research focus is on targeted drug delivery systems to treat lung and liver diseases, and in vitro disease modeling.

 

2

Nano-Carrier based Smart Drug Delivery Systems

Sidharth Mehta

Sidharth Mehta, Researcher in Market Research domain at Prescient Healthcare Group, India. He is a Master’s in Pharmacy (Pharmaceutics) by qualification did his postgraduation from GJUS&T, Hisar, India. His research interests are mainly in the field of nanotechnology. In 2021, he spent a period at University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh (India) with an UGC-NRC project on “Development and Evaluation of Solid Lipid Nanoparticles as Drug Carrier for Topical Delivery of Leflunomide”. He has published several papers in international peer reviewed journals. He had done in-plant training in two pharmaceutical companies and improved his research skill as per industry standards. He worked hard on both his academic and practical skills, as a result of that he qualified national level pharmacy graduate test (GPAT) thrice and NIPER with good rank.

 

Nikita Yadav

Nikita Yadav, she believes that you can achieve anything at any age. She is a Master’s in Pharmacy (Pharmaceutics) by qualification did her postgraduation from GJUS&T, Hisar, India. Her research interests are mainly in the field of nano- and micro-technology with the use of essentials and natural ingredients.  She had many recent experiences like a course in Elsevier[Certified peer reviewer Course], in Good Clinical Practice by NIDA Clinical trials networkandin Regulatory affairs by Udemy.Also, she joined an NGO i.e., Aashman Foundation, which mainly work unconditionally on women empowerment, single income families and underprivileged children through relevant healthcare, innovative education, and environmental based livelihood programs. She also qualified national level pharmacy graduate test (GPAT) in 2020.

 

3

Schedule M guideline: Revision and its nationwide implementation

Dr. M Aamir Mirza

Dr. M. Aamir Mirza is working as an Assistant Professor in the Department of Pharmaceutics, Jamia Hamdard, an NIRF Rank 1 institute and a NAAC ‘A+” grade deemed to be University. He has a multifaceted career portfolio adorned with both industry and academic accomplishments. During his industry stay he became a seasoned scientist and dealt with challenging NCE/NDA development. He is on advisory boards of some international research-based companies of India, New Zealand and Europe. Academics and Research being close to his heart, he has published more than 110 manuscripts in the journals of international repute and has been granted 02 Indian patent and filed for 04. He has contributed several chapters in books published by reputed authors like Elsevier and Bentham. He is amongst the very few scientists globally who has an expertise in Humic substances research. A well-travelled scientist; he has delivered scientific addresses in countries like USA, Austria, Japan, Netherlands, Turkey, Estonia, Spain and Russia. He has been Elite Fellow at University of Malaya (Malaysia) for the last 5 years where he takes classes on the topics related to industrial pharmacy.

5

Navigating Regulatory Frameworks: “Generic Approvals in Latin America’s Two Giants- Brazil & Mexico

Bhavya Sridevi Sundaraneedi

Sundaraneedi Bhavya Sridevi is a Master’s student of Regulatory Affairs at National Institute of Pharmaceutical Education and Research (NIPER- Raebareli). She had a six-month internship experience at Hetero Labs in Regulatory affairs of Latin America. Her interests include global regulatory affairs and Latin American emerging market regulations.

Dr. Rahul Shukla

Dr. Rahul Shukla, Assistant Professor at the Department of Pharmaceutics, NIPER Raebareli, Lucknow, an Institute of National Importance, under the Ministry of Chemicals & Fertilizers, Govt. of India. He was awarded SERB International Research Experience (SIRE) Fellow. Listed in Stanford University's Top 2% Scientists in Pharmaceutical Sciences Worldwide. 
Research Interest: Pharmaceutics, Nanomedicine, Particle Engineering, Bionanomaterials for various therapeutic applications.
 

press releasesRead more...

Approval for Cefiderocol in Australia

Shionogi Co Ltd announced today that it has received marketing authorization from the Therapeutic Goods Administration TGA in Australia for cefiderocol a siderophore cephalosporin developed by Shionogi for the treatment of carbapenemresistant Gramnegative bacterial infections This marketing auth...

Biocon Secures 10-Year Supply Contract for Pertuzumab in Brazil

Biocon Limited an innovationled global biopharmaceuticals company today announced the signing of partnership agreement with Bahiafarma and Bionovis for Pertuzumab in Brazil marking an important milestone

Beyond Annex 1: PDA Aseptic Processing of Biopharmaceuticals Conference 2026 Explores the Future of Sterility Assurance

The Parenteral Drug Association PDA Asia Pacific will host the PDA Aseptic Processing of Biopharmaceuticals Conference on November at the Sheraton Grand Incheon Hotel in Incheon South Korea

ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer

AstraZenecas ETCAMAH camizestrant in combination with a cyclindependent kinase CDK inhibitor abemaciclib palbociclib or ribociclib has been approved in the US for the treatment of adult patients

Global Experts to Gather in Osaka for PDA Aseptic Manufacturing and Regulatory Science Symposium 2026

As pharmaceutical manufacturers worldwide continue to navigate the implementation of PICS GMP Annex a landmark international symposium in Japan will bring together regulators industry leaders

Researchers Gain Faster Access to Complex DNA as Integrated DNA Technologies and Ansa Biotechnologies Expand Ordering Platform

Integrated DNA Technologies IDT a Danaher company and a global leader in genomics and Ansa Biotechnologies Inc a trusted partner for DNA synthesis today announced an expansion of their partnership

EventsRead more...

14 - 15

Sep 2026

16th American DDF Summit

Omni Boston Hotel at the Seapo...

15 - 17

Sep 2026

COPD Drug Development Summit 2026

Street, Boston, MA 02210, USA

21 - 23

Sep 2026

21 - 23

Sep 2026

Cancer R&D World Conference

Hilton Garden Inn Miami Dolphi...

22 - 23

Sep 2026

22 - 24

Sep 2026

28 - 01

Sep 2026

LATEST NEWSRead more...

Rezubio Advances RZ-520 into Phase 1 Clinical Trial Following FDA and NMPA Clearances

Rezubio has announced the first cohort dosing in its Phase clinical trial of RZ following Investigational New Drug IND clearances from the US Food and Drug Administration FDA and Chinas National Medical

ZANVASTRO approved by FDA as first disease-modifying treatment for Alexander disease

Ionis Pharmaceuticals has received approval from the US Food and Drug Administration FDA for ZANVASTRO zilganersen to treat Alexander disease AxD in paediatric and adult patients

Global Experts to Gather in Osaka for PDA Aseptic Manufacturing and Regulatory Science Symposium 2026

As pharmaceutical manufacturers worldwide continue to navigate the implementation of PICS GMP Annex a landmark international symposium in Japan will bring together regulators industry leaders

HUTCHMED Enters into Agreement with GSK for Novel KRAS-EGFR Cancer Therapy

HUTCHMED has entered into an exclusive development and licensing agreement with GSK for HMPLA an investigational antibodytargeted therapy conjugate ATTC designed to target KRAS and EGFR in solid tumours

Everest Medicines Receives Approval for CARDAMYST to Treat Acute PSVT

Everest Medicines has received approval from Chinas National Medical Products Administration NMPA for CARDAMYST etripamil nasal spray for the conversion of acute symptomatic episodes

HUTCHMED Announces Approval of ATLED® (Fanregratinib) for FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma

HUTCHMED has received conditional approval from Chinas National Medical Products Administration NMPA for ATLED fanregratinib to treat adults with advanced metastatic or unresectable intrahepatic cholangiocarcinoma ICC with FGFR fusion or rearrangement who have previously received systemic therapy